The Latest Cardiac and Vascular News
anuary 13, 2025 07:00 AM Eastern Standard Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° […]
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the […]
WEST VALLEY CITY, Utah, Jan. 13, 2025 /PRNewswire/ — Scientia Vascular, a leading innovator in neurovascular medical devices, announces a strategic leadership transition to further drive innovation and growth. Founder and Chief Executive Officer (CEO) John Lippert will transition to the…
Patented SelectFlex™ Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature System enables biaxial approach, regardless of access site, to eliminate complexity and cost of conventional configurations FREMONT,…
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market
SS Innovations International Performs World’s First Robotic Cardiac Telesurgeries with its SSi Mantra 3
YOKNEAM, Israel, Jan. 13, 2025 /PRNewswire/ — ElastiMed Ltd. a leading innovator in wearable medical devices for treating and managing lymphatic and venous diseases, is proud to announce the appointment of Dr. Steve Elias as a member of its Medical Advisory Board, effective immediately….
NEW YORK, Jan. 13, 2025 /PRNewswire/ — WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed a strategic investment in CIVIE (“CIVIE” or the “Company”), an AI-powered ecosystem of radiology solutions. The Company’s…
ENGLEWOOD CLIFFS, N.J., Jan. 13, 2025 /PRNewswire/ — BRAIN.Q, is excited to announce the CE Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide. Reducing stroke disability is often achieved through endovascular…
MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDE Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). This approval allows the trial to take place at institutions that utilize WCG IRB as their central IRB in the United States. Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial.
